Cortistatin: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข3 clinical studies cited
- โขOverall evidence level: low
- โข6 research gaps identified
Research Studies
A cortical neuropeptide with neuronal depressant and sleep-modulating properties
de Lecea L, Criado JR, Prospero-Garcia O, et al. (1996) โข Nature
Discovery paper identifying cortistatin as a novel neuropeptide expressed in cerebral cortex interneurons. ICV administration in rats selectively promoted slow-wave sleep and depressed cortical neuronal activity.
Key Findings
- Novel 14-amino-acid neuropeptide identified in rat cerebral cortex
- Shares 11 of 14 residues with somatostatin but encoded by separate gene
- ICV administration selectively enhances slow-wave sleep in rats
- Depresses cortical neuronal activity by antagonizing acetylcholine
Limitations: Initial discovery study; small sample sizes; limited to rat models; mechanism of sleep promotion not fully elucidated
Cortistatin promotes and negatively correlates with slow-wave sleep
Bourgin P, Fabre V, Huitron-Resendiz S, et al. (2007) โข European Journal of Neuroscience
Follow-up study demonstrating that cortistatin selectively promotes deep slow-wave sleep via EEG synchronization. Preprocortistatin mRNA is inversely correlated with time spent in slow-wave sleep and upregulated by sleep deprivation.
Key Findings
- Cortistatin enhances EEG synchronization and promotes deep slow-wave sleep
- Preprocortistatin mRNA negatively correlates with slow-wave sleep time
- mRNA upregulated after sleep deprivation suggesting homeostatic role
- Circadian rhythm of cortistatin expression demonstrated
Limitations: Rat model only; correlational mRNA data; ICV route not clinically applicable; no dose-response characterization for chronic administration
Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease
Gonzalez-Rey E, Varela N, Sheibanie AF, et al. (2006) โข Proceedings of the National Academy of Sciences
Demonstrated therapeutic efficacy of cortistatin in murine colitis models. Treatment ameliorated clinical and histopathologic severity, downregulated inflammatory cytokines, and prevented disease recurrence.
Key Findings
- Cortistatin significantly ameliorated colitis severity in TNBS and DSS mouse models
- Downregulated TNF-alpha and IL-1beta and Th1 cytokines
- Promoted regulatory T cell generation
- Effective in both prophylactic and therapeutic settings: prevented disease recurrence
Limitations: Mouse models only; short-term treatment duration; systemic IP administration; no human IBD data
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 5+ community reports
View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขNo human clinical trials have been conducted for any indication
- โขBlood-brain barrier penetration limits therapeutic development for neurological applications
- โขShort in vivo half-life requires structural modification for clinical use
- โขSomatostatin receptor cross-reactivity complicates selective targeting
- โขLong-term safety profile completely unknown in humans
- โขCortistatin-selective analogs with improved pharmacokinetics needed for clinical translation
Research Overview#
Cortistatin research spans three decades since its discovery in 1996, with a well-established preclinical evidence base covering sleep neurobiology, anti-inflammatory immunology, and receptor pharmacology. However, all data remains preclinical, and no human clinical trials have been conducted. The evidence level is classified as low due to the exclusively preclinical nature of the research, despite high-quality publications in top-tier journals.
Sleep Neurobiology#
Discovery (Nature 1996)#
The foundational study by de Lecea et al. (PMID 8622767) identified cortistatin through a subtractive hybridization screen for cortex-enriched transcripts. Key findings:
- Cortistatin-14 is produced by a subset of GABAergic interneurons in the cerebral cortex
- ICV administration in rats selectively promotes slow-wave sleep
- Cortistatin depresses cortical neuronal activity, likely by antagonizing acetylcholine
- Despite structural homology with somatostatin, cortistatin's sleep effects are distinct
Sleep Homeostasis (Eur J Neurosci 2007)#
Bourgin et al. (PMID 17686045) expanded the sleep research:
- Cortistatin enhances EEG synchronization during deep slow-wave sleep
- Preprocortistatin mRNA expression inversely correlates with time spent in SWS
- mRNA is upregulated following sleep deprivation, consistent with a homeostatic sleep factor
- Expression follows a circadian rhythm, with peak levels during the active period
BDNF Regulation (Molecular Brain 2011)#
BDNF (brain-derived neurotrophic factor) was identified as a key upstream regulator of cortistatin expression. Activity-dependent BDNF signaling through TrkB receptors controls cortistatin-expressing interneuron function and thereby influences sleep behavior.
Anti-Inflammatory Research#
Inflammatory Bowel Disease (PNAS 2006)#
Gonzalez-Rey et al. (PMID 16537513) demonstrated cortistatin's therapeutic potential in IBD:
- Cortistatin ameliorated clinical and histopathologic severity of colitis in TNBS and DSS mouse models
- Treatment downregulated a broad spectrum of inflammatory mediators (TNF-alpha, IL-1beta, IL-6)
- Cortistatin suppressed Th1-driven autoimmune responses
- Treatment was effective in established colitis and prevented disease recurrence
- Cortistatin promoted regulatory T cell generation and restored mucosal immune tolerance
Sepsis (J Leukoc Biol 2006)#
Cortistatin protected against lethal endotoxemia in mouse models:
- Downregulated inflammatory mediator production by endotoxin-activated macrophages
- Protected against lethality after cecal ligation and puncture
- Reduced systemic inflammatory response to bacterial endotoxin
Arthritis#
Cortistatin demonstrated therapeutic effects in experimental arthritis models:
- Downregulated inflammatory and Th1 responses in joint tissues
- Reduced clinical and histologic severity of arthritis
- Anti-inflammatory mechanism involved both cytokine suppression and Treg induction
Atherosclerosis#
Research in ApoE-deficient mice showed cortistatin reduced atherosclerotic plaque formation and inhibited foam cell formation, suggesting a potential role in cardiovascular inflammation.
Autoimmune Myocarditis (FASEB J 2017)#
Cortistatin attenuated experimental autoimmune myocarditis through inhibition of cardiomyogenic T cell-driven inflammatory responses and promotion of CD25+FoxP3+ regulatory T cells.
Structural Analog Development#
BCN Peptide Analog (Nature Communications 2021)#
A structure-based design approach produced a cortistatin analog with improved selectivity for immunomodulatory pathways and reduced somatostatin receptor cross-reactivity. This analog retained therapeutic efficacy in IBD models while potentially offering improved pharmacokinetic properties for clinical development.
Cortistatin Overexpression Studies#
Transgenic mice overexpressing cortistatin showed deficits in synaptic plasticity and learning, particularly in hippocampal-dependent tasks. This suggests that while acute cortistatin promotes beneficial sleep, chronic overactivation may impair cognitive function, highlighting the importance of physiological dosing levels.
Evidence Quality Assessment#
| Evidence Criterion | Assessment | Details |
|---|---|---|
| Study design | Preclinical only | In vitro and animal models |
| Species studied | Rodents (rat, mouse) | No primate or human data |
| Publication quality | High | Nature, PNAS, FASEB J, Eur J Neurosci |
| Mechanism | Well-characterized | Receptor binding and signaling pathways defined |
| Consistency | High | Sleep and anti-inflammatory effects replicated across labs |
| Clinical translation | Not initiated | No IND or clinical trial filings |
| Safety data | Limited to animals | No human safety data |
| Therapeutic development | Early | Analog design initiated (Nature Comms 2021) |
Related Reading#
Frequently Asked Questions About Cortistatin
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.